FDA Looking To Boost Transparency On How Patient Input Is Used In Drug Reviews

 
• By Sarah Karlin-Smith

Sponsor concerns about commercial confidential information may be a sticking point in getting patient groups the desired data on when and how the FDA uses patient input in regulatory decision making.

close up of gloved hand holding a scalpel
FDA could use a "scalpel" to carefully address commercial confidentiality and share more information with patient groups, an ultra rare disease advocate told the agency. • Source: Shutterstock

More from Rare Diseases

More from Conferences